| Project/Area Number |
11671400
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | ASAHI UNIVERSITY |
|---|
Principal Investigator |
ANDOH Takashi ASAHI UNIVERSITY, NEUROSURGERY, PROFESSOR, 歯学部, 教授 (90126722)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMADA Mikito ASAHI UNIVERSITY, NEUROSURGERY, RESEARCH ASSOCIATE, 歯学部, 助手 (40308672)
KUBOTA Yoshinori ASAHI UNIVERSITY, NEUROSURGERY, ASSOCIATE PROFESSOR, 歯学部, 助教授 (60278207)
SAKAI Noboru GIFU UNIVERSITY, NEUROSURGERY, PROFESSOR, 医学部, 教授 (10021487)
篠田 淳 岐阜大学, 医学部, 助教授 (50273131)
竹中 勝信 岐阜大学, 医学部, 助手 (00283292)
|
|---|
| Project Period (FY) |
1999 – 2000
|
| Project Status |
Completed (Fiscal Year 2000)
|
| Budget Amount *help |
¥2,800,000 (Direct Cost: ¥2,800,000)
Fiscal Year 2000: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1999: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
|---|
| Keywords | primary central nervous system lymphoma / soluble CD27 / soluble interleukin-2 receptor / tumor marker / ELISA / CSF / immunocompetent patient / ELISA / 頭蓋内悪性リンパ腫 / solubleCD27 |
|---|
| Research Abstract |
In the last decade, primary central nervous system(PCNSL)increased in number in immunocompetent populations as well as in immunosuppressed populations. Although recently there are many studies concerning diagnostic methods of acquired immunodeficiency syndrome(AIDS)-related PCNSL, no reliable tumor marker for PCNSL has been identified yet in immunocompetent populations, and at present the precise diagnosis is dependent on the histopathological technique. However, some patients with PCNSL are not suitable for surgical intervention due to physiological or social problems, and other adjunctive diagnostic methods are essential for such patients. Therefore, the aim of our present study is to stimate the diagnostic value of CSF sCD27 as a tumor marker for PCNSL in immunocompetent patients by means of analyzing a total of 93 CSF samples obtained from the following four patient groups : the PCNSL group, the other brain tumors(OBT)group, the other neurological diseases(OND)group, and the inflammatory neurological diseases(IND)group. As a result, the CSF sCD27 levels were over 15 U/ml in 23 of 26 PCNSL samples and in 11 of 12 IND samples. In contrast, the sCD27 levels were below 15 U/ml in the OBT and OND groups. Moreover, the clinical courses and the sCD27 levels correlated very well in two PCNSL patients. Taken together, CSF sCD27 is useful as a tumor marker for PCNSL in immunocompetent patients, and is also useful to evaluate the effect of various types of treatment. Although there was a large cross-reactivity in the sCD27 levels between PCNSL and IND groups, the CSF white blood cell count is helpful to distinguish these two diseases.
|
